Bristol Myers Squibb Presents New Interim Long|Term Efficacy Data ...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data ...

Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 ...

KarXT demonstrated a favorable long-term metabolic profile where ...

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in ...

Bristol Myers Squibb to Present New Clinical and Health Economics ...

Notable data poster presentations include: Clinical : Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia ...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data ...

PRINCETON, N.J., April 06, 2024--BMS Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in ...

Corporate news details - Bristol Myers Squibb

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with ...

Press releases - Corporate financial news - Bristol Myers Squibb

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia ...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data ...

Long-term efficacy data from the trial were presented in a poster titled, “Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in ...

Corporate news details - Bristol Myers Squibb

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp ...

Corporate news details - Bristol Myers Squibb

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with ...

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data ...

... Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma. Download PDF Format (opens in new window). These data represent the ...

Bristol Myers presents new interim long-term efficacy data from ...

Bristol Myers announced new interim results from the Phase 3 EMERGENT-4 open-label extension trial evaluating the long-term efficacy, ...

Bristol Myers Squibb to Present Data at ASCO & EHA from More ...

... long-term benefit for patients.” Key data being presented by Bristol Myers Squibb at ASCO and EHA include: New pivotal data. Progression-free survival and ...

Bristol Myers Squibb to Present Data at the 2024 American Society ...

Among pooled interim data ... long-term studies. Assessing Participant ... Ramsay, I. Poster W52. Low Long-Term Risk of EPS with Muscarinic Agonist ...

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable ...

... and a paid consultant for Bristol Myers Squibb. “These new analyses reinforce the well-established safety and efficacy profile of Zeposia as ...

Bristol-Myers Squibb Company - Drugs.com

... and Drug Administration for Relapsed or Refractory Follicular Lymphoma 15 May 2024; Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from ...

Phase III Trials Show Long-Term Efficacy of Cobenfy Treating ...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 ...

Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential ...

1. Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 ...

Bristol Myers Squibb to Present Data at ESMO Demonstrating ...

Efficacy and safety data from the randomized ... Long-term management and outcomes in gastroesophageal cancer in Norway ... new frontiers in personalized ...

Bristol Myers Squibb to present new clinical and HEOR data on ...

Notable data poster presentations include: Clinical : Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia ...

New Data Demonstrates KarXT's Positive Long-Term Metabolic Profile

Bristol Myers Squibb presents new interim long-term efficacy data from the EMERGENT-4 trial evaluating KarXT in schizophrenia at the 2024 ...